Validation of a host response test to distinguish bacterial and viral respiratory infection. by Lydon, Emily C et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Emergency Medicine Articles Emergency Medicine 
10-1-2019 
Validation of a host response test to distinguish bacterial and viral 
respiratory infection. 
Emily C. Lydon 
Ricardo Henao 
Thomas W. Burke 
Mert Aydin 
Bradly P. Nicholson 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/
emergencymedicine_articles 
Recommended Citation 
Lydon EC, Henao R, Burke TW, Aydin M, Nicholson BP, Glickman SW, Fowler VG, Quackenbush EB, Cairns 
CB, Kingsmore SF, Jaehne AK, Rivers EP, Langley RJ, Petzold E, Ko ER, McClain MT, Ginsburg GS, Woods 
CW, and Tsalik EL. Validation of a host response test to distinguish bacterial and viral respiratory 
infection. EBioMedicine 2019. 
This Article is brought to you for free and open access by the Emergency Medicine at Henry Ford Health System 
Scholarly Commons. It has been accepted for inclusion in Emergency Medicine Articles by an authorized 
administrator of Henry Ford Health System Scholarly Commons. 
Authors 
Emily C. Lydon, Ricardo Henao, Thomas W. Burke, Mert Aydin, Bradly P. Nicholson, Seth W. Glickman, 
Vance G. Fowler, Eugenia B. Quackenbush, Charles Cairns, Stephen F. Kingsmore, Anja K. Jaehne, 
Emanuel P. Rivers, Raymond J. Langley, Elizabeth Petzold, Emily R. Ko, Micah T. McClain, Geoffrey S. 
Ginsburg, Christopher W. Woods, and Ephraim L. Tsalik 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
emergencymedicine_articles/170 
EBioMedicine 48 (2019) 453–461
Contents lists available at ScienceDirect
EBioMedicine
journal homepage: www.elsevier.com/locate/ebiom
Validation of a host response test to distinguish bacterial and viral
respiratory infection
Emily C. Lydona,b, Ricardo Henaoc, Thomas W. Burkeb, Mert Aydinb, Bradly P. Nicholsond,
Seth W. Glickmane, Vance G. Fowler f,g, Eugenia B. Quackenbushe, Charles B. Cairnse,h,
Stephen F. Kingsmore i, Anja K. Jaehnej, Emanuel P. Rivers j, Raymond J. Langleyk,
Elizabeth Petzoldb, Emily R. Kob,l, Micah T. McClainb,m, Geoffrey S. Ginsburgb,
Christopher W. Woodsb,m,∗∗, Ephraim L. Tsalikb,m,∗
aDuke University School of Medicine, Durham, NC, USA
bDuke University Center for Applied Genomics and Precision Medicine, Durham, NC, USA
cDuke University Department of Biostatistics and Informatics, Durham, NC, USA
d Institute of Medical Research, Durham Veterans Affairs Medical Center, Durham, NC, USA
eUniversity of North Carolina Medical Center, Chapel Hill, NC, USA
fDuke University Department of Medicine, Durham, NC, USA
gDuke Clinical Research Institute, Durham, NC, USA
hUnited Arab Emirates University, Al Ain, UAE
i Rady Children’s Institute for Genomic Medicine, San Diego, CA, USA
jHenry Ford Hospital System, Detroit, MI, USA
kUniversity of South Alabama Health University Hospital, Mobile, AL, USA
lDepartment of Hospital Medicine, Duke Regional Hospital, Durham, NC 27705, USA
mDurham Veterans Affairs Health Care System, Durham, NC, USA
a r t i c l e i n f o
Article history:
Received 18 April 2019
Revised 19 September 2019
Accepted 20 September 2019
Available online 17 October 2019
Keywords:
Biomarkers
Gene expression
Respiratory tract infections
Coinfection
Diagnosis
Precision medicine
a b s t r a c t
Background: Distinguishing bacterial and viral respiratory infections is challenging. Novel diagnostics
based on differential host gene expression patterns are promising but have not been translated to a clin-
ical platform nor extensively tested. Here, we validate a microarray-derived host response signature and
explore performance in microbiology-negative and coinfection cases.
Methods: Subjects with acute respiratory illness were enrolled in participating emergency departments.
Reference standard was an adjudicated diagnosis of bacterial infection, viral infection, both, or neither. An
87-transcript signature for distinguishing bacterial, viral, and noninfectious illness was measured from
peripheral blood using RT-PCR. Performance characteristics were evaluated in subjects with confirmed
bacterial, viral, or noninfectious illness. Subjects with bacterial-viral coinfection and microbiologically-
negative suspected bacterial infection were also evaluated. Performance was compared to procalcitonin.
Findings: 151 subjects with microbiologically confirmed, single-etiology illness were tested, yielding AU-
ROCs 0•85–0•89 for bacterial, viral, and noninfectious illness. Accuracy was similar to procalcitonin (88%
vs 83%, p=0•23) for bacterial vs. non-bacterial infection. Whereas procalcitonin cannot distinguish viral
from non-infectious illness, the RT-PCR test had 81% accuracy in making this determination. Bacterial-
viral coinfection was subdivided. Among 19 subjects with bacterial superinfection, the RT-PCR test iden-
tified 95% as bacterial, compared to 68% with procalcitonin (p=0•13). Among 12 subjects with bacterial
infection superimposed on chronic viral infection, the RT-PCR test identified 83% as bacterial, identical to
procalcitonin. 39 subjects had suspected bacterial infection; the RT-PCR test identified bacterial infection
more frequently than procalcitonin (82% vs 64%, p=0•02).
Interpretation: The RT-PCR test offered similar diagnostic performance to procalcitonin in some subgroups
but offered better discrimination in others such as viral vs. non-infectious illness and bacterial/viral coin-
fection. Gene expression-based tests could impact decision-making for acute respiratory illness as well as
a growing number of other infectious and non-infectious diseases.
Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
https://doi.org/10.1016/j.ebiom.2019.09.040
2352-3964/Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Research in context
Evidence before this study: A number of studies have turned
to the human host response as an alternative diagnostic strategy
given the limitations of traditional pathogen-based testing. This
growing body of work includes broad classifiers for identifying the
etiology of respiratory infection, pediatric febrile illness, and sep-
sis, as well as pathogen-specific classifiers for tuberculosis, Lyme
disease, and Ebola, to name a few. While these classifiers are in
various stages of development, very few have undergone extensive
testing or been further developed into a clinically available diag-
nostic test.
Added value of this study: We previously published gene ex-
pression signatures for distinguishing bacterial, viral, and noninfec-
tious causes of respiratory illness using high dimensional ‘omics-
based techniques that had an overall accuracy of 87%. In this study,
we have implemented this signature onto a real-time PCR test and
demonstrated robust performance with AUROCs of 0•85–0•89. Ad-
ditionally, the host response test showed promise in characterizing
more complex phenotypes, including bacterial-viral coinfection and
suspected but not microbiologically confirmed infection. This study
is distinctive in its translation of our signatures to a standardized,
clinic-ready platform and its application to phenotypes that have
previously been excluded from testing.
Implications of all available evidence: The ability of a clinical
test to rapidly identify the presence or absence of an infection
and guide appropriate antibiotic use would improve individual pa-
tient care and mitigate the development of antibiotic resistance.
More generally, host response diagnostic signatures like the one
presented here represent a means by which diagnostics can enable
personalized medicine.
1. Introduction
Difficulty in differentiating bacterial, viral, and noninfectious
etiologies of respiratory illness contributes to antibiotic overuse. In
the U.S., 73% of clinic visits and 61% of emergency department vis-
its for suspected respiratory tract infection led to a prescription for
antibiotics, despite most having a viral etiology [[1],[2]]. Driven by
excess antibiotic use, antibiotic resistance is emerging at an alarm-
ing rate, outpacing novel antibiotic development and contributing
to rising healthcare costs [[3],[4]]. Diagnostic tests that discrimi-
nate these etiologies of illness could individualize care and mit-
igate inappropriate antibiotic use. However, traditional pathogen-
based diagnostics have limited sensitivity, long time-to-result (as
with culture), require a priori suspicion of the pathogen (as with
molecular tests), and cannot differentiate infection from coloniza-
tion.
Measuring the host response offers an alternative diagnostic
strategy. Procalcitonin, preferentially rising in bacterial infections,
has demonstrated clinical utility in safely decreasing antibiotic use,
though that finding was not reproduced in a recent, large, U.S.-
based study [[5],[6]]. With respect to its ability to distinguish bac-
terial and viral etiologies, procalcitonin has shown only modest
performance [7–9]. Biomarker panels that combine multiple ana-
lytes may impart greater sensitivity and specificity. Several stud-
ies have successfully defined signatures that discriminate bacterial
and viral infection using high-dimensional ‘omics-based techniques
[10–16]. However, most signatures have not undergone indepen-
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∗∗ Co-Corresponding author at: 508 Fulton Street, Service 113,Durham, NC 27710,
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dent in vitro validation and typically excluded patients with com-
plex phenotypes, such as the immunocompromised, coinfected,
chronically infected, or clinically ambiguous. Understanding perfor-
mance in these heterogeneous populations is vital for the develop-
ment of this new generation of tests.
We previously published a microarray-derived host gene ex-
pression classifier that accurately distinguished bacterial, viral, and
noninfectious causes of acute respiratory illness [[17],[18]]. We
subsequently translated these signatures onto a real-time PCR test,
a reproducible and standardized diagnostic platform. Here, we val-
idate this test’s ability to discriminate causes of acute respiratory
illness and explore the ability of the host response to character-
ize coinfected, chronically infected, and clinically equivocal cases
as compared to procalcitonin.
2. Materials and methods
2.1. Subject enrollment
Subjects with acute respiratory illness were prospectively en-
rolled in emergency departments at Duke University, Durham VA
Health Care System, Henry Ford Hospital, and University of North
Carolina as part of the CAPSOD (Community-Acquired Pneumonia
and Sepsis Outcome Diagnostics, ClinicalTrials.gov NCT00258869),
CAPSS (Community-Acquired Pneumonia and Sepsis Study), or
RADICAL (Rapid Diagnostics in Categorizing Acute Lung Infection)
studies. All studies were approved by the respective IRBs in accor-
dance with institutional and federal regulations regarding the pro-
tection of human subjects. Written informed consent was obtained
from all subjects or legally authorized representatives.
2.2. Clinical adjudication and subject selection
All subjects enrolled in CAPSOD, CAPSS, and RADICAL under-
went clinical adjudication. This adjudication served as the ref-
erence standard for the study. Adjudications were conducted by
emergency medicine, hospital medicine, pulmonary medicine, or
infectious disease physicians after enrollment but prior to gene ex-
pression or procalcitonin measurements, as previously described
[[17],[19]]. Information supporting adjudication included history,
physical examination, clinical laboratory testing, and radiography.
Supplemental viral PCR testing was performed for all subjects us-
ing the ResPlex 2•0 viral PCR multiplex assay (Qiagen), xTAG RVP
FAST 2 (Luminex), or NxTAG Respiratory Pathogen Panel (Luminex).
Subjects were retrospectively selected for inclusion from the
larger pool of study subjects if they fell into one of several adjudi-
cated categories. A “confirmed” bacterial or viral infection required
the subject to have a compatible clinical syndrome and identified
pathogen. In the absence of supporting microbiological evidence,
adjudicators could still make a classification of “suspected bacte-
rial” or “suspected viral” infection if the clinical presentation was
consistent with this etiology. Adjudicators could identify multiple
infectious etiologies within one subject if multiple pathogens were
identified or if the clinical presentation was consistent with coin-
fection. Adjudication of noninfectious illness was made only when
microbiological testing was negative and an alternative, noninfec-
tious diagnosis was established. Additional details regarding the
clinical adjudication and subject selection processes are available
in the Supplemental Methods section.
2.3. Host gene expression measurement
Peripheral whole blood was collected from each subject at en-
rollment. Total RNA was extracted using PAXgene Blood miRNA
kit (Qiagen). RNA quantity and quality were assessed by Nan-
oDrop Spectrophotometer (Thermo Fisher Scientific) and Aligent
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2100 Bioanalyzer with RNA 6000 Nano kit, respectively. A cDNA
library was generated from total RNA using SuperScript VILO Mas-
terMix (Thermo Fisher Scientific). Semi-quantitative, real-time PCR
was performed on custom TaqMan Low Density Arrays (TLDA)
[[20],[21]]. TLDA cards were customized to quantify 87 RNA tran-
scripts (Table S1). Targets were selected from prior microarray-
based studies in an iterative process, substituting poorly perform-
ing assays with different probes for the same transcript or with
other transcripts that were highly correlated with the original
[[17],[18]]. Additional details can be found in the Supplementary
Methods.
2.4. Model calibration and validation
Due to technical differences between microarray measurements
and RT-PCR, we could not apply the microarray-based model to
this new data. We therefore trained a new model on RT-PCR data.
Specifically, RT-PCR gene expression data were average normal-
ized against two reference transcripts with stable expression across
phenotypes (DECR1 and TRAP1). Data were generated in two dis-
tinct experiments. 19 technical replicates were utilized to assess
model robustness as well as identify potential batch differences,
which were corrected using an empirical Bayesian frameworks
model [22]. Correlation was high for these technical replicates
(R2 =0•96) (Figure S1). Normalized, batch-corrected data from sub-
jects with confirmed bacterial, viral, or noninfectious illness were
used to fit a logistic regression model. Scripts were written in R
using the Glmnet toolbox [23]. Specifically, we used Least Abso-
lute Shrinkage and Selection Operator (LASSO) for regularization
and performed nested cross-validation to select parameters. This
resulted in three independent binary classifiers (bacterial versus
non-bacterial, viral versus non-viral, and noninfectious versus in-
fectious), of which the largest probability determined class. Perfor-
mance metrics included positive percent agreement (PPA), negative
percent agreement (NPA), and area under the receiver operating
characteristic curve (AUROC). The fixed-weight model was then ap-
plied to subjects with coinfection and suspected bacterial infection.
To allow for coinfection, we defined probability thresholds for the
bacterial and viral classifiers allowing us to identify four scenarios:
bacterial infection, viral infection, coinfection, and no infection.
2.5. Procalcitonin comparison
Procalcitonin testing was not obtained as part of clinical care
and was therefore available as an independent comparator with-
out risking incorporation bias. Procalcitonin was measured using
serum or plasma, when available. Serum samples were measured
on the Roche Elecsys 2010 analyzer (Roche Diagnostics) or miniVI-
DAS immunoassay (bioMérieux). Plasma samples were measured
using B•R•A•H•M•S PCT sensitive KRYPTOR (Thermo Fisher Scien-
tific). Measurements were treated equivalently regardless of plat-
form. Values >0•25μg/liter defined bacterial infection and values
≤0•25μg/liter defined non-bacterial [24]. We compared procalci-
tonin and gene expression using McNemar’s test.
3. Results
3.1. Bacterial, viral, and noninfectious classifiers
In the absence of a reliable gold standard to define infection
class, expert clinical adjudication served as the reference standard.
Thus, 151 subjects with adjudicated and microbiologically con-
firmed phenotypes (48 bacterial, 54 viral, 49 noninfectious illness)
were identified to evaluate the RT-PCR test’s performance (Fig. 1).
Instead of healthy individuals, noninfectious illness was selected as
a control group since it represents a clinically relevant population
that would potentially undergo diagnostic testing. Use of this con-
trol population imparts greater specificity to the RT-PCR test. De-
mographically, the cohort was heterogeneous and encompassed a
racially diverse group across a wide age range (Table S2). Groups
were well-balanced with respect to gender and race, though the
viral cohort was younger (mean 42 years vs. 54 for bacterial and
58 for noninfectious) and less ill, as inferred by the rate of hospi-
talization (30%, 96%, and 86%, respectively). Table S3 presents the
bacterial, viral, and noninfectious illness etiologies.
The gene expression signature was first identified in microar-
ray data but validated using RT-PCR. Due to these technical differ-
ences, the models originally generated on microarray data cannot
be applied to RT-PCR data. Instead, retraining classifier parameters
is required. Therefore, RT-PCR gene expression data from these 151
subjects was used to calibrate the classifiers (Table S1). Although
87 gene targets were included in the RT-PCR test, not all were se-
lected and utilized by the model. Specifically, the LASSO methodol-
ogy performed regularization and nested cross-validation to select
model parameters with model weights presented in Table S1. Only
those with non-zero weights were considered informative and re-
tained. This included a total of 41 transcripts: 34 for the bacterial
model, 15 for the viral model, and 8 for the non-infectious illness
model. Some transcripts were utilized for more than one model
explaining why the total parameters for all three models exceeded
41.
Each classifier is binary, and class membership is determined
by the highest of the three probabilities (bacterial, viral, or non-
infectious). Using this methodology, leave-one-out cross-validation
revealed accurate discrimination between groups, with AUROC of
0•85 for bacterial, 0•89 for viral, and 0•88 for noninfectious ill-
ness (Fig. 2). When considering all three classes simultaneously,
the overall accuracy was 77% (116/151 concordant with adjudicated
phenotype). The host gene expression test identified bacterial in-
fection with 75% (36/48) PPA and 92% (95/103) NPA (accuracy 88%).
This performance corresponds to a positive likelihood ratio of 3.68
for ruling in bacterial infection and a negative likelihood ratio of
0.27 for ruling out bacterial infection. Viral infection was identified
with 78% (42/54) PPA and 86% (83/97) NPA (accuracy 82%). With
the noninfectious classifier, infection was correctly excluded in 78%
(38/49) of cases (84% accuracy).
Procalcitonin concentrations were obtained for 137 subjects
with samples available for testing. Procalcitonin correctly classi-
fied 114 of 137 (83%) as either bacterial or non-bacterial, compared
to 121 of 137 (88%) using the host response classifiers (p=0•23)
(Fig. 2). Notably, the performance of the two tests differed based
on the classification task. If excluding the non-infectious illness
group, accuracy was identical for the two tests in distinguishing
bacterial and viral cases (86% vs 86%, p=1). However, the host
response classifiers correctly discriminated bacterial and noninfec-
tious illness more frequently than procalcitonin, though the differ-
ence was not statistically significant (86% vs 77%, p=0•17). Pro-
calcitonin is unable to discriminate viral from non-infectious eti-
ologies. However, the host gene expression test correctly discrimi-
nated these two groups in 81% of cases.
3.2. Performance in complex phenotypes
Having evaluated performance of the RT-PCR test in these sub-
jects with a single, known etiology, we next evaluated a more clin-
ically challenging series of phenotypes: coinfection and suspected
bacterial infection. Since the true state of these subjects was un-
certain, we could not assess performance metrics. Instead, we used
the host gene expression RT-PCR test to characterize their underly-
ing biological state (Fig. 1).
The validation described above utilized the highest predicted
probability as the test result. However, this does not allow for
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Fig. 1. Experimental flow. Coinfection cases included both superinfections (acute bacterial infection following an acute viral infection) and acute-on-chronic coinfections
(acute bacterial infection and chronic viral infection). Suspected bacterial cases were those without microbiological evidence but clinically adjudicated as bacterial. RT-PCR:
Real Time Polymerase Chain Reaction; AoC: acute-on-chronic.
Fig. 2. RT-PCR test performance compared to procalcitonin for microbiologically confirmed, single etiology cases. Upper panels demonstrate AUROC curves for the
bacterial, viral, and noninfectious classifiers. Lower panels show the bacterial, viral, and non-infectious probabilities for each subject, organized by the clinically adjudicated
phenotype. Procalcitonin comparison is shown on the right side of the panel (values are in ng/mL). A maximum procalcitonin value of 10ng/mL was used to improve data
visualization. RT-PCR: Real time polymerase chain reaction; AUROC: area under receiver operator characteristic; NI: non-infectious illness.
the identification of coinfection. We therefore defined probabil-
ity thresholds for the bacterial classifier and the viral classifier.
This scheme allows for the identification of bacterial infection, vi-
ral infection, both, or neither. This approach does not explicitly
use the noninfectious classifier, but the noninfectious subjects are
still utilized in training the bacterial and viral classifiers to in-
crease model specificity. A threshold of 0•45 was set for viral in-
fection and 0•20 for bacterial infection, yielding ≥80% PPA for both
(Figure S2).
The coinfection cohort included 65 subjects (Table S4). Of
this group, 31 had positive testing for both bacterial and viral
pathogens. The remaining 34 had positive microbiology for one
pathogen and a clinical suspicion for the other pathogen class, or a
clinical syndrome consistent with bacterial-viral coinfection. Since
the timeline of coinfection can vary, we created subcategories. “Su-
perinfection” (acute bacterial infection following recent acute viral
infection) included 53 subjects (19 microbiologically confirmed and
34 suspected cases). Of the 19 subjects with microbiologically con-
firmed superinfections, the RT-PCR test identified 18 as having a
bacterial infection (16 as bacterial alone, two as coinfection) with
one subject classified as noninfectious (Fig. 3A). Procalcitonin only
identified 68% (13/19) as bacterial (p=0.13). In contrast, for the 34
subjects with clinically suspected superinfections without confir-
matory microbiology, the RT-PCR test identified an equal number
as bacterial or viral (12 each, 35%), six (18%) as coinfection, and
four (12%) as noninfectious (Fig. 3B). Procalcitonin was positive in
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Fig. 3. Signature application in cases of superinfection. “Superinfection” describes subjects with an acute bacterial infection temporally following an acute viral infection.
The red and black lines (left and right, respectively) depict the thresholds for bacterial infection and viral infection, respectively. The dashed lines divide the subjects into
their model-predicted classes based on thresholding: bacterial infection, viral infection, coinfection, and no infection. 3A, Model application in microbiologically confirmed
superinfections (n=19). 3B, Model application in clinically adjudicated superinfections without microbiological confirmation. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)
Fig. 4. Signature application in cases of acute-on-chronic coinfections. “Acute-on-chronic” coinfection describes subjects with chronic viral infection and acute bacterial
infection. All subjects had microbiologically confirmed acute bacterial infections. The red and black lines (left and right, respectively) show the thresholds for bacterial
infection and viral infection, respectively. The dashed lines divide the subjects into their model-predicted classes based on thresholding: bacterial infection, viral infection,
coinfection, and no infection. 4A, Model application in chronically infected subjects with detectable or unknown viral load (n=8). 3B, Model application in chronically
infected subjects with a suppressed viral load (n=4). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
only 13 subjects (53% vs 38%, p=0•27, for identifying bacterial in-
fection; Table S5).
The “acute-on-chronic” coinfection cohort included 12 subjects
with chronic viral infections (HIV, hepatitis B/C, or CMV) and su-
perimposed acute bacterial infections, all of which were microbio-
logically confirmed. Six subjects had detectable viral loads, two had
unknown viral loads, and four had suppressed viral loads. Those
with detectable or unknown viral loads had a mixed host response:
five (63%) were classified as bacterial, one (13%) as coinfection, one
(13%) as noninfectious, and one (13%) as viral (Fig. 4A). In contrast,
all four individuals with suppressed viral loads had a bacterial host
response (Fig. 4B). Procalcitonin aligned with the RT-PCR test for
each of the 11 subjects in this subcategory that had available pro-
calcitonin resultsFig. 5.
We also applied the RT-PCR test to 39 subjects with a suspected
bacterial infection (Fig. 5). These were subjects who were clinically
adjudicated as having a bacterial infection on clinical grounds (e.g.
radiographic infiltrate, neutrophilic leukocytosis, hypoxia) but no
identified pathogen. Of these, the RT-PCR test identified 29 (74%) as
bacterial, three (8%) as coinfection, five (13%) as noninfectious, and
two (5%) as viral. Procalcitonin identified a bacterial infection in
64% of cases compared to 82% for host gene expression (p=0•02).
4. Discussion
We previously published microarray-based host response sig-
natures that successfully discriminated bacterial, viral, and nonin-
fectious causes of respiratory illness with an overall accuracy of
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Fig. 5. Signature application in cases of suspected bacterial infections. “Suspected bacterial” describes subjects clinically adjudicated as bacterial infection but without
microbiological confirmation (n=39). The red and black lines (left and right, respectively) show the thresholds for bacterial infection and viral infection, respectively. The
dashed lines divide the subjects into their model-predicted classes based on thresholding: bacterial infection, viral infection, coinfection, and no infection. (For interpretation
of the references to color in this figure legend, the reader is referred to the web version of this article.)
87% [17]. Here, we translated those signatures to a RT-PCR plat-
form and demonstrated robust performance when validated in an
independent cohort of microbiologically confirmed bacterial, viral,
or noninfectious cases. With a targeted RT-PCR test, the bacterial,
viral, and noninfectious classifiers had overall accuracies of 88%,
82%, and 84%, respectively (AUROCs 0•85–0•89) compared to an
imperfect reference standard. The corresponding positive and neg-
ative likelihood ratios for bacterial vs. non-bacterial infection were
3.68 and 0.27, respectively. These values in and of themselves are
unlikely to rule in or rule out bacterial infection. However, when
used in conjunction with other clinical data, such a test would
be a valuable adjunct. Furthermore, the likelihood ratios could be
tuned by choosing different statistical cutoffs that incorporate the
clinical significance of false positive and false negative errors. One
statistic that accomplishes this is the average weighted accuracy
[25]. The other validation described in this study was in cases of
bacterial-viral coinfection, successfully identifying a bacterial infec-
tion in nearly all microbiologically confirmed cases even in the
presence of a concurrent viral illness. These encouraging results
suggest that such a host gene expression-based diagnostic test has
the potential to individualize treatment and mitigate inappropriate
antibiotic prescribing.
Other studies have also investigated gene expression-based
classifiers for diagnosing various infections. This growing body of
work includes classifiers for acute respiratory illness [[15],[16]],
sepsis [[26],[27]], and pediatric febrile illness [[14],[28],[29]], as
well as pathogen-specific classifiers for tuberculosis [[30],[31]],
Lyme disease [32], and Ebola [33]. In contrast to most of these
studies, which used microarray or sequencing for signature dis-
covery and validation, we validated signature performance using a
standardized RT-PCR platform. This is particularly notable because
RT-PCR can be readily translated to rapid, clinically relevant plat-
forms [[34],[35]]. Furthermore, our study is distinctive in its explo-
ration of complex phenotypes, including coinfection and indeter-
minate infection. The translation of a bacterial/viral host response
signature to a clinically-relevant platform, as demonstrated in this
study, has significance beyond this application. The advances pre-
sented here illustrate how this approach can be applied to a mul-
titude of infectious diseases (e.g., tuberculosis, sepsis, undifferen-
tiated fever, rickettsial disease) and non-infectious diseases (e.g.,
coronary artery disease, oncology, rheumatoid arthritis, systemic
lupus erythematosus).
The exact incidence of bacterial-viral coinfection in respiratory
tract infection is unclear, with estimates ranging from 7% to 66%
[36–38]. As a result, concerns about coinfection drive a significant
amount of inappropriate antibiotic use even when clinical test-
ing identifies a viral etiology [39]. Understanding signature per-
formance in this population is a critical step toward the adoption
of gene expression-based testing. Most gene expression-focused
studies either exclude this phenotype, have a very small sample
size, or do not explore the multiple different categories of coin-
fection. Therefore, we applied our host response test, which offers
independent probabilities of bacterial and viral infection, to multi-
ple types of coinfection. Among this group, the bacterial host re-
sponse was most often the dominant signature. This may be due
to the temporal nature of the infections. With common superin-
fection scenarios (viral infections followed by a superimposed bac-
terial infection) and acute-on-chronic infections (chronic viral in-
fection with an acute bacterial infection), the bacterial infection is
the more proximate stress on the immune system. Fortunately, this
is clinically desirable: the ability to successfully identify a bacterial
or coinfection signature would promote the appropriate use of an-
tibacterials in this population.
Within the acute-on-chronic subgroup, a notable pattern
emerged based on the level of viremia. The four subjects with sup-
pressed viral loads all had a strong bacterial host response, while
the eight subjects with detectable viral loads had mixed results
with some subjects revealing a prominent viral host response. This
division is supported by earlier work that explored gene expres-
sion in active and suppressed HIV [40–42]. One study performed
gene expression analysis on individuals before and after initiation
of anti-retrovirals and identified several thousand genes with dif-
ferential expression. The genes with the largest fold change in ex-
pression included several interferon-related genes, such as IFI27,
which is a component of the RT-PCR test [40]. Although this sub-
group is small within our study, these results underscore the im-
portance of evaluating future host response classifiers in subjects
with chronic infections like HIV.
E.C. Lydon, R. Henao and T.W. Burke et al. / EBioMedicine 48 (2019) 453–461 459
Individuals with suspected but unconfirmed respiratory infec-
tion represent a challenge from both an antibiotic stewardship
and a diagnostic development standpoint. This situation is very
common; the Etiology of Pneumonia in the Community (EPIC)
study employed extensive microbiological testing in adults hospi-
talized with community acquired pneumonia and did not identify
a pathogen in 62% of cases [43]. With current diagnostics, it is im-
possible to know what proportion of this group can be attributed
to poor pathogen detection sensitivity versus an underlying non-
infectious process. Here, we applied the signatures to 39 subjects
with etiology-negative suspected bacterial cases and found that
82% had a bacterial host response with the rest distributed across
the other diagnostic possibilities. While it is difficult to gauge the
accuracy of the host response signature in any individual subject,
the summary statistics provide insights for these indeterminate pa-
tients in ways that current pathogen-based methods cannot.
In comparison to procalcitonin, the RT-PCR test offered similar
performance in distinguishing bacterial versus non-bacterial infec-
tions (accuracy 88% vs. 83%, p=0•23). Prior studies have shown the
superiority of multi-analyte panels compared to procalcitonin in-
cluding this signature measured using microarrays; we observed a
similar trend though our study was likely underpowered to achieve
statistical significance [[16],[17],[44]]. The difference between host
gene expression and procalcitonin was most pronounced in two
scenarios. The first was based on the inability of procalcitonin
to distinguish viral from non-infectious illness. In contrast, the
host gene expression test correctly classified 81% of these cases.
The second major improvement over procalcitonin was in cases of
bacterial-viral coinfection. This could be explained by prior exper-
iments showing that in human cell lines cultured with both bac-
terial and viral pathogens, viral-induced interferon signaling domi-
nated, resulting in procalcitonin inhibition [45]. These findings rep-
resents an important yet underappreciated limitation of procal-
citonin for which the host gene expression test significantly ad-
vances clinical diagnostics. For example, a recent meta-analysis
evaluating the ability of procalcitonin to distinguish viral from bac-
terial pneumonia revealed only 55% sensitivity and 76% specificity
using established thresholds [9]. It is also important to highlight
that procalcitonin addresses only one diagnostic question: bacte-
rial or non-bacterial infection. It does not discriminate viral infec-
tion from non-infectious illness, nor can it reliably identify bac-
terial/viral co-infection. In contrast, our approach with indepen-
dent bacterial and viral classifiers allows four possible diagnoses:
bacterial infection, viral infection, coinfection, or no infection. De-
spite similar performance for bacterial vs. non-bacterial infection,
the host gene expression test accurately discriminated viral from
non-infectious etiologies and was significantly better at identify-
ing bacterial/viral co-infection compared to procalcitonin. Focusing
exclusively on bacterial vs. non-bacterial classification oversimpli-
fies clinical practice as highlighted by the inability of procalcitonin
to impact antibiotic utilization in a large, U.S.-based randomized
clinical trial . The more comprehensive diagnostic information of-
fered by host gene expression could therefore provide significant
improvements over current methods to identify the cause of acute
respiratory illness.
A host response approach should also be differentiated from a
pathogen-detection strategy. A combination of the two represents
an ideal strategy but is often impractical due to cost and time con-
siderations. Pathogen-detection tests encompass many technolo-
gies including culture, rapid antigen detection tests, and nucleic
acid amplification tests. Advantages and disadvantages of these ap-
proaches have been reviewed elsewhere [46]. However, one of the
limitations common to all is the inability to distinguish infection
from colonization (asymptomatic shedding), which has been ob-
served for all the pathogens included on these various test pan-
els [[47],[48]]. A negative result does not exclude the presence
of that pathogen (due to sampling bias or poor test sensitivity)
nor does it exclude the presence of other pathogens. This concern
also extends to situations where a pathogen detection test is posi-
tive. Specifically, a positive result (even if due to infection and not
colonization) does not exclude the presence of other, undetected
pathogens. All of these limitations are addressed by using a host
gene expression approach that independently provides information
about both bacterial and viral infection. The host gene expression
test described here identifies the presence of a bacterial or viral
infection when positive and also excludes such an infection when
negative.
Perhaps the most significant limitation of the study is the lack
of a gold standard to diagnose bacterial or viral infection. Conse-
quently, discordant classifications could represent errors in adjudi-
cation or in the test. The validation presented here was performed
at two levels. The first included an independent validation of the
signature (the specific combination of gene expression targets) in
subjects with bacterial, viral, or non-infectious illness. The second
validation was of the model (logistic regression model assigning
weights to each mRNA in the signature) in a cohort of subjects
with complex phenotypes. However, we did not validate the model
in an independent cohort of subjects with only a bacterial, viral, or
non-infectious etiology. Doing so would further improve external
validity. Some categories of coinfection, particularly the chronic vi-
ral infection group, were too small to draw definitive conclusions.
Relatedly, we did not have the opportunity to explore rarer types
of coinfection, including acute viral/chronic bacterial infections and
coinfections occurring at distinct anatomic sites (e.g. concurrent
respiratory viral infection and urinary tract infection). While the
cohorts included individuals as young as 14 years, these results
should be validated in younger children. However, the gene expres-
sion signatures themselves were validated in silico in a large cohort
of pediatric cases [17]. Finally, it is important to acknowledge that
the RT-PCR test can only determine pathogen class. In most pa-
tients, this is adequate for guiding antibiotic selection. However, in
sicker, hospitalized patients, knowing the pathogen type and sus-
ceptibility profile can be important for clinical care. Therefore, host
response-based testing should be viewed as part of a comprehen-
sive diagnostic strategy, rather than a replacement for conventional
pathogen-based testing.
Looking forward, the next challenge will be shortening the
turnaround time of the RT-PCR test. The platform described in
this study requires several hours of hands-on processing time,
which is acceptable for most inpatient settings. However, a test
that is simpler to perform and provides more rapid results could
be transformative in primary care or the emergency department.
Further translation of this host response signature is currently un-
derway, with an estimated time-to-result of approximately 45 min
[[34],[35]].
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